This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-31 (canceled).

Claim 32 (previously presented): A process for the preparation of an aqueous dispersion for the preparation of a coating, comprising the steps of:

mixing together at least one fatty acid salt and at least one layer silicate to form a separating agent mixture, and

adding the separating agent mixture to an aqueous suspension of film-forming polymer(s).

Claim 33 (previously presented): The process of claim 32, wherein the film-forming polymer is a mixture of film-forming polymers.

Claim 34 (previously presented): The process of claim 32, wherein the film-forming polymer is a polyacrylate.

Claim 35 (previously presented): The process of claim 34, wherein the polyacrylate is a polymer based on acrylic acid, methacrylic acid, acrylic acid ester or methacrylic acid ester.

Claim 36 (previously presented): The process of claim 32, wherein the fatty acid salt is an alkali metal salt or

an alkaline earth metal salt or an aluminum salt of a fatty acid.

Claim 37 (withdrawn): The process of claim 36, wherein the alkali metal salt or alkaline earth metal salt is a sodium, potassium, magnesium or calcium behenate salt.

Claim 38 (previously presented): The process of claim 36, wherein the alkali metal salt or alkaline earth metal salt is a sodium, potassium, magnesium, calcium or aluminum stearate salt.

Claim 39 (withdrawn): The process of claim 36, wherein the alkaline earth metal salt is a magnesium salt of caprylic acid, capric acid, lauric acid or palmitic acid.

Claim 40 (currently amended): The process of claim 32, wherein the content of fatty acid salt is from 5 to 40% by weight or 10 to 30% by weight, in each cased based on the dry weight of the film-forming polymer.

Claim 41 (previously presented): The process of claim 32, wherein the separating agent mixture comprises talcum, kaolinite, pyrophyllite, attapulgite, sepolite, muscovite, montmorillonite, bentonite, or vermiculite as layer silicate.

Claim 42 (previously presented): The process of claim 32, wherein the content of layer silicate is from 20 to 60% by weight or from 30 to 50% by weight, in each case based on the dry weight of the film-forming polymer.

Claim 43 (previously presented): The process of claim 32, further comprising applying the aqueous coating dispersion to an active-ingredient-containing core by spraying.

Claim 44 (previously presented): The process of claim 43, wherein the spray application step can be carried out using coating pans, fluidized bed, Accela-coater, dip tube or dip blade processes or pen coating.

Claim 45 (previously presented): The process of claim 43, wherein the active-ingredient-containing core is selected from capsules, tablets, pellets, granules, minitablets or micropellets.

Claim 46 (withdrawn): The process of claim 43, wherein the active-ingredient-containing core is an active ingredient crystal.

Claim 47 (currently amended): The process of claim 45, wherein the pellets or micropellets ~~as active ingredient-containing core~~ comprise an inert core which is coated with an active-ingredient-containing coating.

Claim 48 (withdrawn): The process of claim 45, wherein the micropellets are provided as multiple-unit-dosage form.

Claim 49 (withdrawn): The process of claim 47, wherein the micropellets are provided as multiple-unit-dosage form.

Claim 50 (withdrawn): The process of claim 48, wherein the multiple-unit dosage form is in the form of tablets or in capsules.

Claim 51 (withdrawn): The process of claim 49, wherein the multiple-unit dosage form is in the form of tablets or in capsules.

Claim 52 (previously presented): The process of claim 45, wherein the pellets, granules or minitablets are provided as multiple-unit-dosage form.

Claim 53 (previously presented): The process of claim 47, wherein the pellets are provided as multiple-unit-dosage form.

Claim 54 (previously presented): The process of claim 52, wherein the multiple-unit dosage form is in capsules.

Claim 55 (previously presented): The process of claim 53, wherein the multiple-unit dosage form is in capsules.

Claim 56 (previously presented): The process of claim 43, wherein the active ingredient is provided in admixture with pharmaceutically acceptable auxiliaries.

Claims 57-59 (canceled).

Claim 60 (previously presented): The process of claim 43, wherein the active ingredient is selected from metoprolol, bisoprolol, tramadol, morphine, oxycodone, and

hydrocodone, including stereo isomers and pharmaceutically acceptable salts, hydrates and solvates thereof.

Claim 61 (previously presented): The process of claim 43, wherein the active ingredient is metoprolol succinate.